The effects of cannabinoids on serum cortisol and prolactin in humans.
Mohini Ranganathan, Gabriel Braley, Brian Pittman, Thomas B. Cooper, Edward Perry, John H. Krystal, Deepak Cyril D'Souza
Psychopharmacology May 2009 DOI: 10.1007/s00213-008-1422-2 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Pooled analysis of laboratory studies (linear mixed models) Peer reviewed |
|---|---|
| Sample size | 76 |
| Population | Healthy control subjects (n = 36) and frequent users of cannabis (n = 40) |
| Intervention | Delta-9-tetrahydrocannabinol (Delta-9-THC) |
| Duration | Hormone levels measured before and 70 min after each dose |
| Measures | plasma cortisol, plasma prolactin |
| Key points | At socially relevant doses, intravenous Delta-9-THC increased plasma cortisol in a dose-dependent manner, but frequent cannabis users showed blunted increases relative to healthy controls, and frequent users had lower baseline plasma prolactin levels. The authors propose these differences may reflect tolerance to cannabinoid neuroendocrine effects or may instead reflect inherent differences in neuroendocrine function in frequent users. |
Abstract
Cannabis is one of the most widely used illicit substances, and there is growing interest in the therapeutic applications of cannabinoids. While known to modulate neuroendocrine function, the precise acute and chronic dose-related effects of cannabinoids in humans are not well-known. Furthermore, the existing literature on the neuroendocrine effects of cannabinoids is limited by small sample sizes (n = 6-22), heterogeneous samples with regard to cannabis exposure (lumping users and nonusers), lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose-response data. Delta-9-tetrahydrocannabinol (Delta-9-THC) was hypothesized to produce dose-related increases in plasma cortisol levels and decreases in plasma prolactin levels. Furthermore, relative to controls, frequent users of cannabis were hypothesized to show altered baseline levels of these hormones and blunted Delta-9-THC-induced changes of these hormones. Pooled data from a series of laboratory studies with multiple doses of intravenous Delta-9-THC in healthy control subjects (n = 36) and frequent users of cannabis (n = 40) was examined to characterize the acute, chronic, and acute on chronic effects of cannabinoids on plasma cortisol and prolactin levels. Hormone levels were measured before (baseline) and 70 min after administration of each dose of Delta-9-THC. Data were analyzed using linear mixed models with +70 min hormonal levels as the dependant variable and baseline hormonal level as the covariate. At socially relevant doses, Delta-9-THC raised plasma cortisol levels in a dose-dependent manner but frequent users showed blunted increases relative to healthy controls. Frequent users also had lower baseline plasma prolactin levels relative to healthy controls. These group differences may be related to the development of tolerance to the neuroendocrine effects of cannabinoids. Alternatively, these results may reflect inherent differences in neuroendocrine function in frequent users of cannabis and not a consequence of cannabis use.
Citations in the library
Cited by 15
- Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study Cannabis and Cannabinoid Research December 9, 2022
- Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9-Tetrahydrocannabinol Without Improving Its Analgesic Properties. Clinical Pharmacology & Therapeutics November 1, 2024
- Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs Brain Sciences March 13, 2018
- Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance. Neuroscience & Biobehavioral Reviews December 2022
- Cannabis use and the development of tolerance: a systematic review of human evidence. Neuroscience & Biobehavioral Reviews October 2018
and 10 more in the library
Cites 4
- Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology September 2008
- Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology July 2008
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
- Acute effects of smoking marijuana on hormones, subjective effects and performance in male human subjects. Pharmacology, Biochemistry, and Behavior June 1986